Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu, Qingwei Zhao, Tingbo Liang, Yunqing Qiu
doi: https://doi.org/10.1101/2020.04.29.20085761
Yan Lou
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Lin Liu
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Hangping Yao
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Xingjiang Hu
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Junwei Su
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Kaijin Xu
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Rui Luo
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Xi Yang
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Lingjuan He
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Xiaoyang Lu
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Qingwei Zhao
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Tingbo Liang
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Yunqing Qiu
1State Key Laboratory for diagnosis and treatment of infectious diseases, Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Posted May 05, 2020.
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu, Qingwei Zhao, Tingbo Liang, Yunqing Qiu
medRxiv 2020.04.29.20085761; doi: https://doi.org/10.1101/2020.04.29.20085761
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
Yan Lou, Lin Liu, Hangping Yao, Xingjiang Hu, Junwei Su, Kaijin Xu, Rui Luo, Xi Yang, Lingjuan He, Xiaoyang Lu, Qingwei Zhao, Tingbo Liang, Yunqing Qiu
medRxiv 2020.04.29.20085761; doi: https://doi.org/10.1101/2020.04.29.20085761
Subject Area
Subject Areas
- Addiction Medicine (383)
- Allergy and Immunology (699)
- Anesthesia (192)
- Cardiovascular Medicine (2841)
- Dermatology (243)
- Emergency Medicine (428)
- Epidemiology (12551)
- Forensic Medicine (10)
- Gastroenterology (803)
- Genetic and Genomic Medicine (4428)
- Geriatric Medicine (401)
- Health Economics (715)
- Health Informatics (2849)
- Health Policy (1047)
- Hematology (375)
- HIV/AIDS (893)
- Medical Education (413)
- Medical Ethics (114)
- Nephrology (461)
- Neurology (4186)
- Nursing (222)
- Nutrition (617)
- Oncology (2201)
- Ophthalmology (623)
- Orthopedics (254)
- Otolaryngology (318)
- Pain Medicine (267)
- Palliative Medicine (81)
- Pathology (486)
- Pediatrics (1171)
- Primary Care Research (482)
- Public and Global Health (6775)
- Radiology and Imaging (1487)
- Respiratory Medicine (899)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (200)
- Urology (174)